middle.news

IDT Australia Narrows FY26 EBITDA Loss 85% with $7.3M Capex Boost

10:35am on Thursday 20th of August, 2026 AEST Pharmaceuticals
Read Story

IDT Australia Narrows FY26 EBITDA Loss 85% with $7.3M Capex Boost

10:35am on Thursday 20th of August, 2026 AEST
Key Points
  • FY26 revenue up 3.4% to $20.5 million
  • Net loss shrinks 66% to $2.7 million
  • EBITDA loss narrows 85% to $0.9 million
  • $7.3 million capex program to expand sterile and solid oral manufacturing
Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about Idt Australia (ASX:IDT)
OPEN ARTICLE